Abstract
Sickle cell disease (SCD) is a potentially devastating and life threatening condition that is caused by an autosomal recessive inherited hemoglobinopathy which results in vaso-occlusive phenomena and hemolysis. The severity of this disorder is widely variable, but overall mortality is increased and life expectancy decreased when compared to the general population.
Care of patients with sickle cell disease is largely supportive. In fact, hydroxyurea is the only drug used that modifies disease pathogenesis. Painful vaso-occlusive events are the most common complication experienced by both children and adults with sickle cell disease and hydroxyurea is the only treatment option available to prevent the development of these events. Most events are managed with traditional supportive care measures (i.e. aggressive hydration, antiinflammatory and narcotic analgesics) that have not changed in decades. As such, there is an overwhelming need for both the development of new agents and new approaches to treatment with existing modalities for patients with sickle cell disease.
Keywords: Sickle cell disease, therapeutics, treatment, children.
Current Pharmaceutical Design
Title:Pharmacotherapy of Sickle Cell Disease in Children
Volume: 21 Issue: 39
Author(s): Kathleen A. Neville and Julie A. Panepinto
Affiliation:
Keywords: Sickle cell disease, therapeutics, treatment, children.
Abstract: Sickle cell disease (SCD) is a potentially devastating and life threatening condition that is caused by an autosomal recessive inherited hemoglobinopathy which results in vaso-occlusive phenomena and hemolysis. The severity of this disorder is widely variable, but overall mortality is increased and life expectancy decreased when compared to the general population.
Care of patients with sickle cell disease is largely supportive. In fact, hydroxyurea is the only drug used that modifies disease pathogenesis. Painful vaso-occlusive events are the most common complication experienced by both children and adults with sickle cell disease and hydroxyurea is the only treatment option available to prevent the development of these events. Most events are managed with traditional supportive care measures (i.e. aggressive hydration, antiinflammatory and narcotic analgesics) that have not changed in decades. As such, there is an overwhelming need for both the development of new agents and new approaches to treatment with existing modalities for patients with sickle cell disease.
Export Options
About this article
Cite this article as:
A. Neville Kathleen and A. Panepinto Julie, Pharmacotherapy of Sickle Cell Disease in Children, Current Pharmaceutical Design 2015; 21 (39) . https://dx.doi.org/10.2174/1381612821666151030105213
DOI https://dx.doi.org/10.2174/1381612821666151030105213 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does Daily Dialysis Improve Hypertension in Chronic Haemodialysis Patients?
Current Hypertension Reviews Treatment of Leukoaraiosis: A Futuristic View
Current Drug Targets Emerging Anti-inflammatory Therapies for Atherosclerosis
Current Pharmaceutical Design Proteomic Analysis of Liver Diseases: Molecular Mechanisms and Biomarker Discovery
Mini-Reviews in Medicinal Chemistry Indications, Implications and Applications of Renal Denervation. Have we Discovered Something new?
Current Hypertension Reviews Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Outcomes and Considerations in Hypoplastic Left Heart Syndrome
Current Pediatric Reviews The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships
Current Proteomics Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry Biological Signals Sensing with Wearable Technologies and an ECG Athlete Design
Recent Patents on Biomedical Engineering (Discontinued) A Palliative Care Approach to the Advanced Heart Failure Patient
Current Cardiology Reviews Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends
Current Pharmaceutical Design Metabolic and Cardiovascular Ageing Indices in Relation to Glycated Haemoglobin in Healthy and Diabetic Subjects
Current Aging Science Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies
Current Medicinal Chemistry Vascular Risk Factors and Alzheimer’s Disease Pathogenesis: Are Conventional Pharmacological Approaches Protective For Cognitive Decline Progression?
CNS & Neurological Disorders - Drug Targets